Page 1

Exhibit 99.1 Natera Reports First Quarter 2021 Financial Results AUSTIN , Texas , May 6 , 2021 / PRNewswire / - Natera , Inc. ( NASDAQ : NTRA ) , a pioneer and global leader in cell - free DNA testing , today reported financial results for the first quarter ended March 31 , 2021 and provided an update on recent business progress and financial outlook . Recent Accomplishments & Highlights • Generated total revenues of $ 152.3 million in the first quarter of 2021 compared to $ 94.0 million in the first quarter of 2020 , an increase of 62 % . Product revenues grew 36 % over the same period . First quarter 2021 revenues include a one - time revenue recognition of $ 28.6 million from the conclusion of the Qiagen partnership . • • · • • • Processed approximately 348,200 tests in the first quarter of 2021 , compared to approximately 235,500 tests processed in the first quarter of 2020 , an increase of 48 % . Raising full year 2021 revenue guidance by $ 50M given overall strong momentum . Implemented first wave of Panorama AI improvements with immediate impact on test performance , patient experience and cost of goods sold . Received new local coverage decision from CMS which opens the pathway to Prospera reimbursement in multiple organs . Initiated second phase 3 trial with Genentech using Signatera as a companion diagnostic in early - stage muscle invasive bladder cancer . Received two additional breakthrough device designations for Signatera in new indications . Positive Signatera data presented in ovarian cancer at AACR and multiple myeloma data expected at ASCO . " Q1 was yet another record quarter for Natera , " said Steve Chapman , Natera's Chief Executive Officer . " Our volumes continued to accelerate , we launched Panorama AI , and we expanded our market opportunity with positive new data in both organ health and oncology . As a result of our Q1 performance and the current momentum in the business , we are increasing our revenue forecast for the year by $ 50 million . " First Quarter Ended March 31 , 2021 Financial Results Total revenues were $ 152.3 million in the first quarter of 2021 compared to $ 94.0 million for the first quarter of 2020 , an increase of 62 % . The product revenues were $ 118.4 million in the first quarter of 2021 compared to $ 87.0 million in the first quarter of 2020 , an increase of 36 % . The increase in product revenues was driven by an increase in test volumes compared to the first quarter of 2020. Licensing and other revenues increased by approximately $ 27.0 million over the same period , mainly due to revenue recognized from the Qiagen arrangement of approximately $ 28.6 million of previously deferred revenue . Natera processed approximately 348,200 tests in the first quarter of 2021 , including approximately 333,400 tests accessioned in its laboratory , compared to approximately 235,500 tests processed , including approximately 222,400 tests accessioned in its laboratory , in the first quarter of 2020 .